Company Performance Metrics
- Fabian Svara: Co-Founder and Chief Executive Officer
- Dr. Jörgen Kornfeld: Co-Founder and Scientific Advisor
ariadne.ai ag is a technology leader in high-throughput image analysis and spatial omics data interpretation, accelerating drug discovery with a particular focus on neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
As a software-based Contract Research Organization (CRO), we offer advanced, AI-driven solutions for extracting
meaningful biological insights from a wide range of microscopy data—including confocal, brightfield, and electron microscopy—as well as from spatial omics experiments.
Our expertise spans:
Automated, scalable image analysis across all major microscopy platforms, enabling reproducible quantification for immunohistochemistry, high-content screening, and 3D tissue models.
Spatial omics analytics for biomarker discovery and disease characterization, including spatial transcriptomics and spatial proteomics.
Custom AI pipelines tailored to complex biological questions—from morphometric profiling of astrocytes and microglia to quantitative plaque and tangle classification.
Cloud-based infrastructure for secure, high-throughput data processing—no coding or specialized hardware required.
Scientific consulting on experimental design, image acquisition, and multimodal data integration.
Our flagship platform, SPATIAL, is a cloud-native suite for spatial biology analysis. It streamlines the entire pipeline—from raw image preprocessing to segmentation, feature extraction, and statistical evaluation—across both classical imaging and cutting-edge omics data.
Whether for spatial biology or other imaging-based applications, ariadne.ai delivers the automation, precision, and scalability needed to accelerate research and discovery.
